Condition
Severe Chronic Neutropenia
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 4 (1)
Trial Status
Terminated2
Enrolling By Invitation1
Clinical Trials (3)
Showing 3 of 3 trials
NCT01852370Phase 1Enrolling By Invitation
Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
NCT01859637Phase 4TerminatedPrimary
Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia
NCT00909584Phase 2TerminatedPrimary
Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia
Showing all 3 trials